Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 91

1.

[Clinical features of adult-onset chronic active Epstein-Barr virus infection].

Kawamoto K, Miyoshi H, Seto M, Kimura H, Ohshima K.

Rinsho Ketsueki. 2019;60(8):944-952. doi: 10.11406/rinketsu.60.944. Japanese.

PMID:
31484894
2.

Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.

Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, Sato K, Sasaki Y, Kawamoto K, Shimono J, Yamada K, Muto R, Kizaki M, Nagafuji K, Tamaru JI, Tokuhira M, Ohshima K.

Am J Surg Pathol. 2019 Jul;43(7):869-884. doi: 10.1097/PAS.0000000000001271.

PMID:
31116708
3.

Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.

Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, Nagata Y, Shiraishi Y, Chiba K, Tanaka H, Zhao L, Ochi Y, Takeuchi Y, Takeda J, Ueno H, Kogure Y, Shiozawa Y, Kakiuchi N, Yoshizato T, Nakagawa MM, Nanya Y, Yoshida K, Makishima H, Sanada M, Sakata-Yanagimoto M, Chiba S, Matsuoka R, Noguchi M, Hiramoto N, Ishikawa T, Kitagawa J, Nakamura N, Tsurumi H, Miyazaki T, Kito Y, Miyano S, Shimoda K, Takeuchi K, Ohshima K, Yoshino T, Ogawa S, Kataoka K.

Leukemia. 2019 Dec;33(12):2867-2883. doi: 10.1038/s41375-019-0473-1. Epub 2019 May 15.

PMID:
31092896
4.

Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).

Kawano N, Yoshida N, Kawano S, Arakawa F, Miyoshi H, Yamada K, Nakashima K, Yoshida S, Kuriyama T, Tochigi T, Nakaike T, Shimokawa T, Yamashita K, Marutsuka K, Mashiba K, Kikuchi I, Ohshima K.

Intern Med. 2019 Aug 1;58(15):2159-2166. doi: 10.2169/internalmedicine.2513-18. Epub 2019 Apr 17.

5.

Expression of GLUT1 in Pseudopalisaded and Perivascular Tumor Cells Is an Independent Prognostic Factor for Patients With Glioblastomas.

Komaki S, Sugita Y, Furuta T, Yamada K, Moritsubo M, Abe H, Akiba J, Miyagi N, Nakamura H, Miyoshi H, Ohshima K, Morioka M.

J Neuropathol Exp Neurol. 2019 May 1;78(5):389-397. doi: 10.1093/jnen/nly124.

6.

Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases.

Satou A, Tabata T, Miyoshi H, Kohno K, Suzuki Y, Yamashita D, Shimada K, Kawasaki T, Sato Y, Yoshino T, Ohshima K, Takahara T, Tsuzuki T, Nakamura S.

Mod Pathol. 2019 Jul;32(8):1135-1146. doi: 10.1038/s41379-019-0264-2. Epub 2019 Apr 5.

PMID:
30952973
7.

Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma.

Shimono J, Miyoshi H, Arakawa F, Yamada K, Sugio T, Miyawaki K, Eto T, Miyagishima T, Kato K, Nagafuji K, Akashi K, Teshima T, Ohshima K.

Ann Hematol. 2019 May;98(5):1197-1207. doi: 10.1007/s00277-019-03628-8. Epub 2019 Feb 7.

PMID:
30729289
8.

Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.

Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, Kogure Y, Sato Y, Nishida K, Gion Y, Shiraishi Y, Tanaka H, Chiba K, Watatani Y, Kakiuchi N, Shiozawa Y, Yoshizato T, Yoshida K, Makishima H, Sanada M, Onozawa M, Teshima T, Yoshiki Y, Ishida T, Suzuki K, Shimada K, Tomita A, Kato M, Ota Y, Izutsu K, Demachi-Okamura A, Akatsuka Y, Miyano S, Yoshino T, Gaulard P, Hermine O, Takeuchi K, Ohshima K, Ogawa S.

Leukemia. 2019 Jul;33(7):1687-1699. doi: 10.1038/s41375-019-0380-5. Epub 2019 Jan 25.

9.

Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma.

Takeuchi M, Miyoshi H, Asano N, Yoshida N, Yamada K, Yanagida E, Moritsubo M, Nakata M, Umeno T, Suzuki T, Komaki S, Muta H, Furuta T, Seto M, Ohshima K.

Haematologica. 2019 Aug;104(8):1626-1632. doi: 10.3324/haematol.2018.205567. Epub 2019 Jan 10.

10.

Safety and effective salvage regimen comprising a novel combination of brentuximab vedotin, L-asparaginase, and dexamethasone for refractory anaplastic large cell lymphoma, anaplastic lymphoma kinase negative.

Kawamoto K, Suzuki T, Kasami T, Kiryu M, Sone H, Miyoshi H, Ohshima K, Takizawa J.

Hematol Oncol. 2019 Apr;37(2):212-214. doi: 10.1002/hon.2565. Epub 2018 Nov 19. No abstract available.

PMID:
30394560
11.

Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification.

Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K, Yanagida E, Yamada K, Ohshima K.

Cancer Med. 2018 Nov;7(11):5843-5858. doi: 10.1002/cam4.1805. Epub 2018 Oct 11.

12.

Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis.

Shimono J, Miyoshi H, Yoshida N, Kato T, Sato K, Sugio T, Miyawaki K, Kurita D, Sasaki Y, Kawamoto K, Imaizumi Y, Kato K, Nagafuji K, Akashi K, Seto M, Teshima T, Ohshima K.

Am J Surg Pathol. 2018 Nov;42(11):1466-1471. doi: 10.1097/PAS.0000000000000969.

13.

Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy.

Matsukawa T, Suto K, Miyoshi H, Oshimi K, Ohshima K, Miyagishima T.

J Clin Exp Hematop. 2018 Dec 13;58(4):184-187. doi: 10.3960/jslrt.18027. Epub 2018 Oct 10. No abstract available.

14.

Synchronous case of follicular lymphoma and Langerhans cell sarcoma in the same lymph node.

Shimono J, Miyoshi H, Arakawa F, Abe H, Miyagishima T, Akiba J, Teshima T, Ohshima K.

Pathol Int. 2018 Nov;68(11):614-617. doi: 10.1111/pin.12722. Epub 2018 Sep 25.

PMID:
30255584
15.

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.

Mitobe M, Kawamoto K, Suzuki T, Kiryu M, Tamura S, Nanba A, Suwabe T, Tanaka T, Fuse K, Shibasaki Y, Masuko M, Miyoshi H, Ohshima K, Sone H, Takizawa J.

Intern Med. 2019 Feb 15;58(4):575-580. doi: 10.2169/internalmedicine.1686-18. Epub 2018 Sep 12.

16.

Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.

Sugio T, Miyawaki K, Kato K, Sasaki K, Yamada K, Iqbal J, Miyamoto T, Ohshima K, Maeda T, Miyoshi H, Akashi K.

Blood Adv. 2018 Sep 11;2(17):2242-2252. doi: 10.1182/bloodadvances.2018018754.

17.

Clinicopathological and immunohistochemical analysis of autoimmune regulator expression in patients with osteosarcoma.

Matsuda K, Miyoshi H, Moritsubo M, Hiraoka K, Hamada T, Shiba N, Ohshima K.

Clin Exp Metastasis. 2018 Oct;35(7):641-648. doi: 10.1007/s10585-018-9928-4. Epub 2018 Aug 18.

PMID:
30121939
18.

Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.

Matsuda K, Miyoshi H, Hiraoka K, Hamada T, Nakashima K, Shiba N, Ohshima K.

Clin Orthop Relat Res. 2018 Sep;476(9):1848-1855. doi: 10.1097/CORR.0000000000000379.

19.

Methotrexate-associated lymphoproliferative disorders with angioimmunoblastic T-cell lymphoma-like features accompanied by gamma-heavy chain disease in a patient with rheumatoid arthritis.

Kiyasu J, Arakawa F, Haji S, Tachikawa Y, Tsuda M, Tsukamoto Y, Ikeda M, Muta H, Matsushima T, Miyoshi H, Shiratsuchi M, Ogawa Y, Ohshima K, Yufu Y.

Pathol Int. 2018 Jul 10. doi: 10.1111/pin.12703. [Epub ahead of print]

PMID:
29987858
20.

Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis.

Matsuda K, Miyoshi H, Hiraoka K, Hamada T, Yoshida S, Ishibashi Y, Haraguchi T, Shiba N, Ohshima K.

Clin Exp Med. 2018 Nov;18(4):487-494. doi: 10.1007/s10238-018-0515-4. Epub 2018 Jun 30.

PMID:
29961175

Supplemental Content

Loading ...
Support Center